Filter Results:
(580)
Show Results For
- All HBS Web
(1,289)
- People (5)
- News (400)
- Research (580)
- Multimedia (6)
- Faculty Publications (125)
Show Results For
- All HBS Web
(1,289)
- People (5)
- News (400)
- Research (580)
- Multimedia (6)
- Faculty Publications (125)
Sort by
- 2013
- Case
Advanced Leadership Pathways: General Gale Pollock and Services for the Vision Impaired
By: Rosabeth M. Kanter, Juliane Calingo Schwetz and Patricia Bissett Higgins
In July 2012, retired United States Army Major General Gale Pollock created Elevivo, a venture that worked on developing a comprehensive disease management software system to support the growing number of visually impaired individuals by providing them with tailored... View Details
Keywords: Disease Management; Health; Health Care and Treatment; Education; Information Technology; Insurance; Entrepreneurship; Leadership; Information Technology Industry; Health Industry; United States
Kanter, Rosabeth M., Juliane Calingo Schwetz, and Patricia Bissett Higgins. "Advanced Leadership Pathways: General Gale Pollock and Services for the Vision Impaired." Harvard Business Publishing Case 314-029, 2013.
- March 2014 (Revised February 2015)
- Case
Loki Capital Management
By: Joseph B. Fuller, Shikhar Ghosh and Matthew Preble
In December 2013, Michael Kane was preparing to launch his start-up's first hedge fund. While pleased with the development of the business, he wanted to address a few lingering issues before going any further. He debated whether or not to fire the company's chief... View Details
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details
Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry
Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
- January 2005 (Revised March 2006)
- Case
Molecular Insight Pharmaceuticals, Inc.
By: Richard G. Hamermesh and Edwin W. Parkinson III
Molecular Insight has developed a novel biopharmaceutical to detect heart attacks. The company's unique approach to intellectual property protection uses the Hatch Waxman Act and the Orphan Drug Act. The company is struggling to raise $7 million in Series B financing.... View Details
Keywords: Intellectual Property; Health Care and Treatment; Pharmaceutical Industry; Health Industry
Hamermesh, Richard G., and Edwin W. Parkinson III. "Molecular Insight Pharmaceuticals, Inc." Harvard Business School Case 805-067, January 2005. (Revised March 2006.)
- 29 Jan 2019
- First Look
New Research and Ideas, January 29, 2019
David Grabowski, and David Cutler Abstract— Medicare’s Hospital Readmissions Reduction Program (HRRP) has been credited with lowering risk-adjusted readmission rates for targeted conditions at general acute care hospitals. However, these... View Details
Keywords: Dina Gerdeman
- 26 May 2015
- First Look
First Look: May 26
http://hrleadsbusiness.org/rise-of-hr-e-book May 2015 JAMA, the Journal of the American Medical Association Medicine's Continuous Improvement Imperative By: Huckman, Robert S., and Ananth Raman Abstract— Maintaining quality and spurring... View Details
Keywords: Sean Silverthorne
- 26 Mar 2024
- Research & Ideas
How Humans Outshine AI in Adapting to Change
continuously understand where they are in the world and what problem they are solving in response to changing circumstances far better than current AI does.” “The current way to achieve this feat with AI is to throw a lot of data at it... View Details
- June 2023
- Case
Verve Therapeutics: Taking DNA Editing to Heart
By: Shikhar Ghosh and Shweta Bagai
Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing... View Details
Keywords: AI; Genetic Engineering; Medicine; Health Care and Treatment; Genetics; Innovation Strategy; Business and Stakeholder Relations; Medical Specialties; Innovation and Invention; Entrepreneurship; Biotechnology Industry
Ghosh, Shikhar, and Shweta Bagai. "Verve Therapeutics: Taking DNA Editing to Heart." Harvard Business School Case 823-113, June 2023.
- 19 Mar 2008
- Research & Ideas
Finding Success in the Middle of the Market
services. Very careful cost and service tradeoffs are required of companies that continue to dominate the middle ground. Nowhere is controlling midfield more important than politics. With just two mainstream... View Details
- 23 Jan 2024
- Research & Ideas
How to Keep Employees Productive: Support Caregivers
furtively wedged between meetings and deadlines. Shifts to remote work and flexible hours during early pandemic lockdowns, for example, made care obligations less secretive. But it might not persist: About 50 percent of employers plan to... View Details
Keywords: by Kara Baskin
- 09 Feb 2009
- Research & Ideas
Uncompromising Leadership in Tough Times
upbeat. Senior management continued to invest in the Dreyer Leadership University [DLU], demonstrating that they cared about employee development. Cronk and others in senior management thought this was an... View Details
Keywords: by Martha Lagace
- 17 May 2017
- Research & Ideas
Minorities Who 'Whiten' Job Resumes Get More Interviews
applying for jobs with employers who said they care about diversity. One black student explained in an interview that with each resume she sent out, she weighed whether to include her involvement in a black student organization: “If the... View Details
Keywords: by Dina Gerdeman
- 02 Aug 2011
- First Look
First Look: August 2
Japanese system, combining its traditional low-cost manufacturing prowess with an ability to bring high-quality, high-margin branded products swiftly to market. Like Samsung, today's emerging giants—Haier in China, Infosys in India, and Koç in Turkey, for instance—face... View Details
Keywords: Sean Silverthorne
- October 2022
- Case
Afrigen Biologics: Vaccines for the Global South
By: Debora L. Spar and Julia Comeau
The majority of vaccines used on the continent of Africa (99%) are produced offshore. This makes African nations reliant on the West for major health care needs, a problem which was exacerbated by the COVID-19 pandemic. Afrigen Biologics (in partnership with the WHO)... View Details
Keywords: Vaccination; Vaccine; mRNA; COVID; COVID-19; Inequity; Hub-and-spoke; Health Care and Treatment; Health Pandemics; Production; Social Issues; Business and Government Relations; South Africa; Africa
Spar, Debora L., and Julia Comeau. "Afrigen Biologics: Vaccines for the Global South." Harvard Business School Case 323-030, October 2022.
- 23 Jan 2008
- First Look
First Look: January 23, 2008
hourly wage. The entrepreneurial venture's donors were, however, significantly younger, more likely to be from a minority group, and more likely to have died from cancer. For-profit organizations, continuing medical training... View Details
Keywords: Martha Lagace
- September–October 2020
- Article
The Past, Present, and (Near) Future of Gene Therapy and Gene Editing
By: Julia Pian, Amitabh Chandra and Ariel Dora Stern
Emerging gene therapy and gene-editing technologies will have a growing impact on patient lives and health-care delivery. We analyzed a decade of data on clinical trials and venture capital investments to understand the likely trajectory of genetically focused... View Details
Keywords: Gene Therapy; Gene Editing; Impact; Health Care and Treatment; Technological Innovation; Health Testing and Trials; Venture Capital; Change
Pian, Julia, Amitabh Chandra, and Ariel Dora Stern. "The Past, Present, and (Near) Future of Gene Therapy and Gene Editing." NEJM Catalyst Innovations in Care Delivery 1, no. 5 (September–October 2020).
- Article
Assessing the Food and Drug Administration's Risk-Based Framework for Software Precertification with Top Health Apps in the United States: Quality Improvement Study
By: Noy Alon, Ariel Dora Stern and John Torous
BACKGROUND: As the development of mobile health apps continues to accelerate, the need to implement a framework that can standardize categorizing these apps to allow for efficient, yet robust regulation grows. However, regulators and researchers are faced with numerous... View Details
Keywords: Mobile Health; Smartphone; Food And Drug Administration; Risk-based Framework; Health Care and Treatment; Mobile and Wireless Technology; Applications and Software; Framework
Alon, Noy, Ariel Dora Stern, and John Torous. "Assessing the Food and Drug Administration's Risk-Based Framework for Software Precertification with Top Health Apps in the United States: Quality Improvement Study." JMIR mHealth and uHealth 8, no. 10 (October 2020).
- 17 Jan 2023
- In Practice
8 Trends to Watch in 2023
As 2023 begins, businesses and employees face an uncertain economy and labor market, as the twin dilemmas of inflation and interest rates weigh on forecasts. Harvard Business School faculty share the top trends that they believe will shape the workplace and markets... View Details
Keywords: by Avery Forman
- 15 Mar 2024
- HBS Case
Let's Talk: Why It's Time to Stop Avoiding Taboo Topics at Work
place, discussing one’s next step (or departure) wouldn’t feel abrupt or discriminatory. Health Wing works with a company that saw almost a million dollars in unexpected health care costs last year because the company’s generous health... View Details
Keywords: by Avery Forman
- October 2024
- Supplement
NOW PT (B)
By: George A Riedel, Allison J. Wigen and Dave Habeeb
Pre-Abstract: Instructors should consider the timing of making videos available to students, as they may reveal key case details.
Abstract: In fall 2021, a team of students from the HBS Impact Investing Fund considered Neurologic Optimal Wellness Physical Therapy... View Details
Riedel, George A., Allison J. Wigen, and Dave Habeeb. "NOW PT (B)." Harvard Business School Multimedia/Video Supplement 325-702, October 2024.